1. Home
  2. SMCI vs BIIB Comparison

SMCI vs BIIB Comparison

Compare SMCI & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super Micro Computer Inc.

SMCI

Super Micro Computer Inc.

N/A

Current Price

$31.75

Market Cap

20.1B

Sector

Technology

ML Signal

N/A

Logo Biogen Inc.

BIIB

Biogen Inc.

N/A

Current Price

$190.46

Market Cap

27.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SMCI
BIIB
Founded
1993
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.1B
27.1B
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
SMCI
BIIB
Price
$31.75
$190.46
Analyst Decision
Hold
Buy
Analyst Count
16
27
Target Price
$39.53
$194.72
AVG Volume (30 Days)
19.6M
886.7K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.86
8.79
Revenue
$2,484,929,000.00
$9,890,600,000.00
Revenue This Year
$90.56
N/A
Revenue Next Year
$19.83
N/A
P/E Ratio
$37.07
$21.43
Revenue Growth
11.68
2.22
52 Week Low
$27.61
$110.04
52 Week High
$62.36
$202.41

Technical Indicators

Market Signals
Indicator
SMCI
BIIB
Relative Strength Index (RSI) 50.27 52.25
Support Level $28.90 $170.99
Resistance Level $33.18 $202.41
Average True Range (ATR) 1.56 5.34
MACD -0.01 -1.04
Stochastic Oscillator 49.58 47.54

Price Performance

Historical Comparison
SMCI
BIIB

About SMCI Super Micro Computer Inc.

Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: